Circulation

Vol. 154, Issue 5 Issue 5 2026
15
Articles

Articles in this Issue

Perspectives on the Future of Fundamental Sciences in Cardiovascular Medicine

Joseph C. Wu Aug 04, 2026 pp. 425-427 10.1161/circulationaha.126.080164

Correction to: 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Latha P. Palaniappan, Norrina B. Allen, Zaid I. Almarzooq et al. Aug 04, 2026 10.1161/cir.0000000000001469

Loss of STMP1 Perturbs Mitochondrial Cristae and Drives Cellular Inflammation and Heart Failure

Francesco Paolo Ruberto, Chang Jie Mick Lee, Matthew Ackers-Johnson et al. Aug 04, 2026 pp. 454-473 10.1161/circulationaha.124.073677

BACKGROUND: Heart failure is a leading cause of morbidity and mortality worldwide, particularly among the growing elderly population. In degenerative aging and autoimmune diseases,...

Left Ventricular Hypertrabeculation and Prognosis in Dilated Cardiomyopathy

Nerea Mora-Ayestarán, Noemi Ramos-Lopez, Juan Pablo Ochoa et al. Aug 04, 2026 pp. 440-453 10.1161/circulationaha.125.078536

BACKGROUND: Left ventricular (LV) hypertrabeculation, formerly termed LV noncompaction, is a heterogeneous myocardial entity linked to adverse cardiovascular outcomes. This study e...

Strategies for Optimizing Heart Failure Care in the Older Adult: A Scientific Statement From the American Heart Association

Sabra C. Lewsey, Trejeeve Martyn, Vanessa Blumer et al. Aug 04, 2026 10.1161/cir.0000000000001437

Heart failure prevalence is increasing and has a disproportionate burden on older adults. Older adults, however, may encounter unique challenges in accessing and navigating comprehensive disease-modif...

Late Gadolinium Enhancement in Nonischemic Dilated Cardiomyopathy

Betty Raman, Sanjay K. Prasad Aug 04, 2026 pp. 512-516 10.1161/circulationaha.126.079395

Letter by Wang and Wang Regarding Article, “Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial”

Congxiao Wang, Hujun Wang Aug 04, 2026 10.1161/circulationaha.126.080024

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association

Ana Barac, Avirup Guha, Thomas R. Fleming et al. Aug 04, 2026 10.1161/cir.0000000000001417

The unprecedented expansion of approved oncology therapies has prolonged survival and transformed the prognosis for many patients diagnosed with cancer. However, cancer treatments may be associated wi...

Ten Years of Scientific Discovery With the UK Biobank Cardiovascular Magnetic Resonance Imaging Study

Zahra Raisi-Estabragh, Steffen E. Petersen, Stefan Neubauer Aug 04, 2026 pp. 490-511 10.1161/circulationaha.126.080790

The UK Biobank Imaging Study, with its dedicated cardiovascular magnetic resonance substudy, has redefined the scale and scope of cardiovascular research, generating high-quality imaging in 100 000 pa...

SREBP1 Transactivation of NHE3 Impairs Cardiac Contraction and Aggravates Heart Failure

Huijun Gu, Jianpei Wen, Yiyi Liu et al. Aug 04, 2026 pp. 474-489 10.1161/circulationaha.126.079823

BACKGROUND: Heart failure with reduced ejection fraction (HFrEF) is characterized by impaired contractility and high mortality. Dysregulation of intracellula...

Association of Pulmonary Vascular Remodeling With Cardiac Structure and Function, Pulmonary Pressure, and Heart Failure in Late Life: The Atherosclerosis Risk in Communities (ARIC) Study

Aditya Dewanjee, Victoria Lamberson, Yimin Yang et al. Aug 04, 2026 pp. 428-439 10.1161/circulationaha.125.077856

BACKGROUND: Aging is associated with increases in pulmonary pressure related to concomitant age-associated left ventricular remodeling, diastolic dysfunction, and declines in pulmo...

Correction to: Forecasting the Burden of Cardiovascular Disease and Stroke in Women in the United States through 2050: A Scientific Statement from the American Heart Association

Karen E. Joynt Maddox, Harmony R. Reynolds, Demilade Adedinsewo et al. Aug 04, 2026 10.1161/cir.0000000000001470

Response by DeRubertis et al to Letter Regarding Article, “Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial”

Brian G. DeRubertis, Sahil A. Parikh, Ramon L. Varcoe Aug 04, 2026 10.1161/circulationaha.126.079060

Response by Fearon et al to Letter Regarding Article, “Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial”

William F. Fearon, Kuniaki Takahashi, Kiran K. Khush Aug 04, 2026 10.1161/circulationaha.126.080757

Letter by Chen et al Regarding Article, “Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial”

Qingyu Chen, Sujing Jiang, Ruoshu Duan Aug 04, 2026 10.1161/circulationaha.125.078086

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0009-7322
E-ISSN 1524-4539
Subject Health Sciences
Language English
View Full Journal Page